Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 154 No. 5 (2024)

Long-term levels of protection of different types of immunity against the Omicron variant: a rapid literature review

  • Sabina Rodriguez Velásquez
  • Loza Estifanos Biru
  • Sandrine Marie Hakiza
  • Muaamar Al-Gobari
  • Isotta Triulzi
  • Jyoti Dalal
  • Camille Beatrice Gaza Varela
  • Sara Botero Mesa
  • Olivia Keiser
DOI
https://doi.org/10.57187/s.3732
Cite this as:
Swiss Med Wkly. 2024;154:3732
Published
06.05.2024

Summary

INTRODUCTION: With the emergence of newer SARS-CoV-2 variants and their substantial effects on the levels and duration of protection against infection, an understanding of these characteristics of the protection conferred by humoral and cellular immunity can aid in the proper development and implementation of vaccine and safety guidelines.

METHODS: We conducted a rapid literature review and searched five electronic databases weekly from 1 November 2021 to 30 September 2022. Studies that assessed the humoral or cellular immunity conferred by infection, vaccination or a hybrid (combination of both) in adults and risk groups (immunocompromised and older populations) were identified. Studies were eligible when they reported data on immunological assays of COVID-19 (related to vaccination and/or infection) or the effectiveness of protection (related to the effectiveness of vaccination and/or infection).

RESULTS: We screened 5103 studies and included 205 studies, of which 70 provided data on the duration of protection against SARS-CoV-2 infection. The duration of protection of adaptive immunity was greatly impacted by Omicron and its subvariants: levels of protection were low by 3–6 months from exposure to infection/vaccination. Although more durable, cellular immunity also showed signs of waning by 6 months. First and second mRNA vaccine booster doses increased the levels of protection against infection and severe disease from Omicron and its subvariants but continued to demonstrate a high degree of waning over time.

CONCLUSION: All humoral immunities (infection-acquired, vaccine-acquired and hybrid) waned by 3–6 months. Cellular immunity was more durable but showed signs of waning by 6 months. Hybrid immunity had the highest magnitude of protection against SARS-CoV-2 infection. Boosting may be recommended as early as 3–4 months after the last dose, especially in risk groups.

References

  1. Chen CP, Huang KA, Shih SR, Lin YC, Cheng CY, Huang YC, et al. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. Microbiol Spectr. 2022 Aug;10(4):e0074322. 10.1128/spectrum.00743-22 DOI: https://doi.org/10.1128/spectrum.00743-22
  2. Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020 Oct;20(10):581–2. 10.1038/s41577-020-00436-4 DOI: https://doi.org/10.1038/s41577-020-00436-4
  3. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Mutations of SARS-CoV-2 spike protein: implications on immune evasion and vaccine-induced immunity. Semin Immunol. 2021 Jun;55:101533. 10.1016/j.smim.2021.101533 DOI: https://doi.org/10.1016/j.smim.2021.101533
  4. Hu J, Peng P, Wang K, Fang L, Luo FY, Jin AS, et al. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cell Mol Immunol. 2021 Apr;18(4):1061–3. 10.1038/s41423-021-00648-1 DOI: https://doi.org/10.1038/s41423-021-00648-1
  5. Hirabara SM, Serdan TD, Gorjao R, Masi LN, Pithon-Curi TC, Covas DT, et al. SARS-COV-2 Variants: Differences and Potential of Immune Evasion. Front Cell Infect Microbiol. 2022 Jan;11:781429. 10.3389/fcimb.2021.781429 DOI: https://doi.org/10.3389/fcimb.2021.781429
  6. McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022 Feb;375(6583):864–8. 10.1126/science.abn8652 DOI: https://doi.org/10.1126/science.abn8652
  7. Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, et al.; DMID 21-0012 Study Group. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 Jul;3(7):100679. 10.1016/j.xcrm.2022.100679 DOI: https://doi.org/10.2139/ssrn.4061187
  8. Mise-Omata S, Ikeda M, Takeshita M, Uwamino Y, Wakui M, Arai T, et al. Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant. J Immunol. 2022 Dec;209(11):2104–13. 10.4049/jimmunol.2200525 DOI: https://doi.org/10.4049/jimmunol.2200525
  9. Kurhade C, Zou J, Xia H, Cai H, Yang Q, Cutler M, et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun. 2022 Jun;13(1):3602. 10.1038/s41467-022-30681-1 DOI: https://doi.org/10.1038/s41467-022-30681-1
  10. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa. N Engl J Med. 2022 Oct;387(14):1332–3. 10.1056/NEJMc2210093 DOI: https://doi.org/10.1056/NEJMc2210093
  11. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016 Dec;5(1):210. 10.1186/s13643-016-0384-4 DOI: https://doi.org/10.1186/s13643-016-0384-4
  12. Wang Z, Yang X, Mei X, Zhou Y, Tang Z, Li G, et al. SARS-CoV-2-specific CD4+ T cells are associated with long-term persistence of neutralizing antibodies. Signal Transduct Target Ther. 2022 Apr;7(1):132. 10.1038/s41392-022-00978-0 DOI: https://doi.org/10.1038/s41392-022-00978-0
  13. Garcia-Valtanen P, Hope CM, Masavuli MG, Yeow AE, Balachandran H, Mekonnen ZA, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Rep Med. 2022 Jun;3(6):100651. 10.1016/j.xcrm.2022.100651 DOI: https://doi.org/10.1016/j.xcrm.2022.100651
  14. Guo L, Zhang Q, Zhang C, Huang T, Ren L, Cao B, et al. Assessment of Antibody and T-Cell Responses to the SARS-CoV-2 Virus and Omicron Variant in Unvaccinated Individuals Recovered From COVID-19 Infection in Wuhan, China. JAMA Netw Open. 2022 Apr;5(4):e229199. 10.1001/jamanetworkopen.2022.9199 DOI: https://doi.org/10.1001/jamanetworkopen.2022.9199
  15. Li Y, Wang X, Shen XR, Geng R, Xie N, Han JF, et al. A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity. Emerg Microbes Infect. 2022 Dec;11(1):902–13. 10.1080/22221751.2022.2049984 DOI: https://doi.org/10.1080/22221751.2022.2049984
  16. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med. 2022 Jul;387(1):21–34. 10.1056/NEJMoa2203965 DOI: https://doi.org/10.1056/NEJMoa2203965
  17. Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, et al. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada. JAMA Netw Open. 2022 Oct;5(10):e2236670. 10.1001/jamanetworkopen.2022.36670 DOI: https://doi.org/10.1001/jamanetworkopen.2022.36670
  18. Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe. 2022 Dec;3(12):e944–55. 10.1016/S2666-5247(22)00287-7 DOI: https://doi.org/10.1016/S2666-5247(22)00287-7
  19. Šmíd M, Berec L, Přibylová L, Májek O, Pavlík T, Jarkovský J, et al. Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 [Erratum in: J Infect Dis. 2023 Apr 18;227] [8] [:1021-1022. PMID: 35482442; PMCID: PMC9129207]. J Infect Dis. 2022 Oct;226(8):1385–90. 10.1093/infdis/jiac161
  20. Belik M, Jalkanen P, Lundberg R, Reinholm A, Laine L, Väisänen E, et al. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants. Nat Commun. 2022 May;13(1):2476. 10.1038/s41467-022-30162-5 DOI: https://doi.org/10.1038/s41467-022-30162-5
  21. Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, et al. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Netw Open. 2022 May;5(5):e2210780. 10.1001/jamanetworkopen.2022.10780 DOI: https://doi.org/10.1001/jamanetworkopen.2022.10780
  22. Lu L, Mok BW, Chen LL, Chan JM, Tsang OT, Lam BH, et al. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clin Infect Dis. 2022 Aug;75(1):e822–6. 10.1093/cid/ciab1041 DOI: https://doi.org/10.1093/cid/ciab1041
  23. Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022 Feb;375(6581):678–80. 10.1126/science.abn7591 DOI: https://doi.org/10.1126/science.abn7591
  24. Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, et al. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Med (N Y). 2022 Jun;3(6):406–421.e4. 10.1016/j.medj.2022.04.013 DOI: https://doi.org/10.1016/j.medj.2022.04.013
  25. Xia H, Zou J, Kurhade C, Cai H, Yang Q, Cutler M, et al. Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine. bioRxiv 2022.01.21.476344; doi: https://doi.org/10.1101/2022.01.21.476344 DOI: https://doi.org/10.1101/2022.01.21.476344
  26. Adachi E, Nagai E, Saito M, Isobe M, Konuma T, Koga M, et al. Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. J Infect Chemother. 2022 Jul;28(7):1015–7. 10.1016/j.jiac.2022.03.021 DOI: https://doi.org/10.1016/j.jiac.2022.03.021
  27. Hein S, Mhedhbi I, Zahn T, Sabino C, Benz NI, Husria Y, et al. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination. Vaccines (Basel). 2022 May;10(5):796. 10.3390/vaccines10050796 DOI: https://doi.org/10.3390/vaccines10050796
  28. Woldemeskel BA, Garliss CC, Aytenfisu TY, Johnston TS, Beck EJ, Dykema AG, et al. SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. JCI Insight. 2022 May;7(10):e159474. 10.1172/jci.insight.159474 DOI: https://doi.org/10.1172/jci.insight.159474
  29. Gilboa M, Regev-Yochay G, Mandelboim M, Indenbaum V, Asraf K, Fluss R, et al.; Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection, JAMA Netw. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. JAMA Netw Open. 2022 Sep;5(9):e2231778. 10.1001/jamanetworkopen.2022.31778 DOI: https://doi.org/10.1001/jamanetworkopen.2022.31778
  30. Richardson JR, Götz R, Mayr V, Lohse MJ, Holthoff HP, Ungerer M. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection. PLoS One. 2022 Apr;17(4):e0266701. 10.1371/journal.pone.0266701 DOI: https://doi.org/10.1371/journal.pone.0266701
  31. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr;386(16):1532–46. 10.1056/NEJMoa2119451
  32. Wang X, Chang H, Tian H, Zhu Y, Li J, Wei Z, et al. Epidemiological and clinical features of SARS-CoV-2 infection in children during the outbreak of Omicron variant in Shanghai, March 7-31, 2022. Influenza Other Respir Viruses. 2022 Nov;16(6):1059–65. 10.1111/irv.13044 DOI: https://doi.org/10.1111/irv.13044
  33. Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022 Mar;77:103904. 10.1016/j.ebiom.2022.103904 DOI: https://doi.org/10.1016/j.ebiom.2022.103904
  34. GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S, et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022 Mar;7(69):eabo2202. 10.1126/sciimmunol.abo2202 DOI: https://doi.org/10.1126/sciimmunol.abo2202
  35. Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, et al. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci Immunol. 2022 Apr;7(70):eabn8590. 10.1126/sciimmunol.abn8590 DOI: https://doi.org/10.1126/sciimmunol.abn8590
  36. Sablerolles RS, Rietdijk WJ, Goorhuis A, Postma DF, Visser LG, Schmitz KS, et al.; SWITCH Research Group. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clin Infect Dis. 2023 Feb;76(3):e533–6. 10.1093/cid/ciac495 DOI: https://doi.org/10.1093/cid/ciac495
  37. Tan CS, Collier AY, Yu J, Liu J, Chandrashekar A, McMahan K, et al. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. JAMA Netw Open. 2022 Aug;5(8):e2226335. 10.1001/jamanetworkopen.2022.26335 DOI: https://doi.org/10.1001/jamanetworkopen.2022.26335
  38. Reinscheid M, Luxenburger H, Karl V, Graeser A, Giese S, Ciminski K, et al. COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. Nat Commun. 2022 Aug;13(1):4631. 10.1038/s41467-022-32324-x DOI: https://doi.org/10.1038/s41467-022-32324-x
  39. Chang MR, Ke H, Coherd CD, Wang Y, Mashima K, Kastrunes GM, Huang CY, Marasco WA. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. EBioMedicine. 2022 Jun;80:104025. doi: 10.1016/j.ebiom.2022.104025. Epub 2022 May 6. PMID: 35533497; PMCID: PMC9073271.https://doi.org/10.1016/j.ebiom.2022.104025. DOI: https://doi.org/10.1016/j.ebiom.2022.104025
  40. Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, et al. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. J Med Virol. 2023 Jan;95(1):e28164. 10.1002/jmv.28164 DOI: https://doi.org/10.1002/jmv.28164
  41. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022 Mar;14(637):eabn8057. 10.1126/scitranslmed.abn8057 DOI: https://doi.org/10.1126/scitranslmed.abn8057
  42. Edara VV, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep Med. 2022 Jan;3(2):100529. 10.1016/j.xcrm.2022.100529 DOI: https://doi.org/10.1016/j.xcrm.2022.100529
  43. Qu P, Faraone JN, Evans JP, Zheng YM, Yu L, Ma Q, et al. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med. 2022 Oct;387(14):1329–31. 10.1056/NEJMc2210546 DOI: https://doi.org/10.1056/NEJMc2210546
  44. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, Florentino PT, Penna GO, Pearce N, et al. Vaccination plus previous infection: protection during the omicron wave in Brazil. Lancet Infect Dis. 2022 Jul;22(7):945–6. 10.1016/S1473-3099(22)00288-2 DOI: https://doi.org/10.1016/S1473-3099(22)00288-2
  45. McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EH, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study [Erratum in: Lancet Infect Dis. 2022 Sep;22] [9] [:e239. PMID: 35850128; PMCID: PMC9286709]. Lancet Infect Dis. 2022 Oct;22(10):1435–43. 10.1016/S1473-3099(22)00345-0
  46. Al Jurdi A, Gassen RB, Borges TJ, Lape IT, Morena L, Efe O, et al. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients. Kidney Int. 2022 Jun;101(6):1282–6. 10.1016/j.kint.2022.04.009 DOI: https://doi.org/10.1016/j.kint.2022.04.009
  47. Carr EJ, Wu M, Harvey R, Billany RE, Wall EC, Kelly G, et al.; Haemodialysis COVID-19 Consortium, Crick COVID Immunity Pipeline. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. Lancet. 2022 Feb;399(10327):800–2. 10.1016/S0140-6736(22)00104-0 DOI: https://doi.org/10.1016/S0140-6736(22)00104-0
  48. Becker M, Cossmann A, Lürken K, Junker D, Gruber J, Juengling J, et al. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients. Front Immunol. 2022 Oct;13:1004045. 10.3389/fimmu.2022.1004045 DOI: https://doi.org/10.3389/fimmu.2022.1004045
  49. Cheng CC, Platen L, Christa C, Tellenbach M, Kappler V, Bester R, et al. Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients. Vaccines (Basel). 2022 Aug;10(8):1328. 10.3390/vaccines10081328 DOI: https://doi.org/10.3390/vaccines10081328
  50. Di Giacomo AM, Giacobini G, Anichini G, Gandolfo C, D’alonzo V, Calabrò L, et al. SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines. Eur J Cancer. 2022 Aug;171:143–9. 10.1016/j.ejca.2022.05.018 DOI: https://doi.org/10.1016/j.ejca.2022.05.018
  51. Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AE, van Doesum JA, van Binnendijk RS, et al.; COBRA KAI Study Team. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19. JAMA Oncol. 2022 Oct;8(10):1477–83. 10.1001/jamaoncol.2022.3227
  52. Karaba AH, Johnston TS, Aytenfisu TY, Akinde O, Eby Y, Ruff JE, et al. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. Transplantation. 2022 Jul;106(7):1440–4. 10.1097/TP.0000000000004140 DOI: https://doi.org/10.1097/TP.0000000000004140
  53. Kennedy NA, et al. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut. 2022 Jul;•••: 10.1136/gutjnl-2022-327570 DOI: https://doi.org/10.1136/gutjnl-2022-327570
  54. Kontopoulou K, Nakas CT, Belai C, Papazisis G. Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 vaccine in immunocompromised adults in Greece: is a fourth dose necessary? J Med Virol. 2022 Oct;94(10):5056–60. 10.1002/jmv.27954 DOI: https://doi.org/10.1002/jmv.27954
  55. Montez-Rath ME, Garcia P, Han J, Cadden L, Hunsader P, Morgan C, et al. SARS-CoV-2 Infection during the Omicron Surge among Patients Receiving Dialysis: The Role of Circulating Receptor-Binding Domain Antibodies and Vaccine Doses. J Am Soc Nephrol. 2022 Oct;33(10):1832–9. 10.1681/ASN.2022040504 DOI: https://doi.org/10.1681/ASN.2022040504
  56. Otto C, Schwarz T, Jeworowski LM, Schmidt ML, Walper F, Pache F, et al. Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinations. medRxiv 2022.08.10.22278639; doi: https://doi.org/10.1101/2022.08.10.22278639 DOI: https://doi.org/10.1101/2022.08.10.22278639
  57. Thakkar A, Pradhan K, Duva B, Carreno JM, Sahu S, Thiruthuvanathan V, et al. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. eLife. 2023 Mar;12:e83694. 10.7554/eLife.83694 DOI: https://doi.org/10.7554/eLife.83694
  58. Tillmann FP, Figiel L, Ricken J, Still H, Korte C, Plaßmann G, et al. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study. J Clin Med. 2022 Jun;11(11):3187. 10.3390/jcm11113187 DOI: https://doi.org/10.3390/jcm11113187
  59. Vergori A, Cozzi-Lepri A, Matusali G, Colavita F, Cicalini S, Gallì P, et al.; HIV-VAC Study Group. SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH. Viruses. 2022 Aug;14(8):1710. 10.3390/v14081710 DOI: https://doi.org/10.3390/v14081710
  60. Kumar D, Hu Q, Samson R, Ferreira VH, Hall VG, Ierullo M, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am J Transplant. 2022 Aug;22(8):2089–93. 10.1111/ajt.17020 DOI: https://doi.org/10.1111/ajt.17020
  61. Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Serra F, et al. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern. ESMO Open. 2022 Oct;7(5):100574. 10.1016/j.esmoop.2022.100574 DOI: https://doi.org/10.1016/j.esmoop.2022.100574
  62. Sanders JF, Messchendorp AL, de Vries RD, Baan CC, van Baarle D, van Binnendijk R, et al.; VACcination Immune Response Study (RECOVAC) Collaborators. Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Clin Infect Dis. 2023 Feb;76(3):e188–99. 10.1093/cid/ciac557 DOI: https://doi.org/10.2139/ssrn.4070419
  63. Madelon N, Heikkilä N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, et al. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 2022 Apr;79(4):399–404. 10.1001/jamaneurol.2022.0245 DOI: https://doi.org/10.1001/jamaneurol.2022.0245
  64. Qui M, Le Bert N, Chan WP, Tan M, Hang SK, Hariharaputran S, et al. Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies. J Clin Invest. 2022 Jun;132(12):e159500. 10.1172/JCI159500 DOI: https://doi.org/10.1172/JCI159500
  65. Peled Y, Afek A, Kreiss Y, Rahav G, Nemet I, Kliker L, et al. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant. J Heart Lung Transplant. 2022 Oct;41(10):1417–25. 10.1016/j.healun.2022.05.014 DOI: https://doi.org/10.1016/j.healun.2022.05.014
  66. Lin FJ, Doss AM, Davis-Adams HG, Adams LJ, Hanson CH, VanBlargan LA, et al. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients. Front Immunol. 2022 Dec;13:1033770. 10.3389/fimmu.2022.1033770 DOI: https://doi.org/10.3389/fimmu.2022.1033770
  67. Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Alessio N, et al. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study. ESMO Open. 2022 Apr;7(2):100458. 10.1016/j.esmoop.2022.100458 DOI: https://doi.org/10.1016/j.esmoop.2022.100458
  68. Sannier G, Nicolas A, Dubé M, Marchitto L, Nayrac M, Tastet O, et al. A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile. Cell Rep Med. 2023 Mar;4(3):100955. 10.1016/j.xcrm.2023.100955 DOI: https://doi.org/10.1016/j.xcrm.2023.100955
  69. Thümmler L, Gäckler A, Bormann M, Ciesek S, Widera M, Rohn H, et al. Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients. Vaccines (Basel). 2022 Aug;10(8):1348. 10.3390/vaccines10081348 DOI: https://doi.org/10.3390/vaccines10081348
  70. Newman J, Thakur N, Peacock TP, Bialy D, Elrefaey AM, Bogaardt C, et al. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nat Microbiol. 2022 Aug;7(8):1180–8. 10.1038/s41564-022-01163-3 DOI: https://doi.org/10.1038/s41564-022-01163-3
  71. Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, et al. Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. J Infect Dis. 2022 Sep;226(6):983–94. 10.1093/infdis/jiac199 DOI: https://doi.org/10.1093/infdis/jiac199
  72. Lee HK, Knabl L, Moliva JI, Knabl L Sr, Werner AP, Boyoglu-Barnum S, et al. mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. Cell Rep. 2022 Apr;39(2):110680. 10.1016/j.celrep.2022.110680 DOI: https://doi.org/10.1016/j.celrep.2022.110680
  73. Giménez E, Albert E, Zulaica J, Torres I, Rusu L, Moreno AR, et al.; Valencian Vaccine Research Program (ProVaVac) Study Group. Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine. Clin Infect Dis. 2022 Aug;75(1):e865–8. 10.1093/cid/ciac223 DOI: https://doi.org/10.1093/cid/ciac223
  74. Renia L, Goh YS, Rouers A, Le Bert N, Chia WN, Chavatte JM, et al.; SCOPE Cohort Study Group. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nat Commun. 2022 Aug;13(1):4615. 10.1038/s41467-022-32312-1 DOI: https://doi.org/10.1038/s41467-022-32312-1
  75. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022 May;386(18):1712–20. 10.1056/NEJMoa2201570 DOI: https://doi.org/10.1056/NEJMoa2201570
  76. Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2022 Apr;386(17):1603–14. 10.1056/NEJMoa2201688 DOI: https://doi.org/10.1056/NEJMoa2201688
  77. Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infect Dis. 2022 Nov;22(1):816. 10.1186/s12879-022-07814-4 DOI: https://doi.org/10.1186/s12879-022-07814-4
  78. Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. BMJ. 2022 May;377:e071113. 10.1136/bmj-2022-071113 DOI: https://doi.org/10.1136/bmj-2022-071113
  79. Higdon MM, Baidya A, Walter KK, Patel MK, Issa H, Espié E, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect Dis. 2022 Aug;22(8):1114–6. 10.1016/S1473-3099(22)00409-1 DOI: https://doi.org/10.1016/S1473-3099(22)00409-1
  80. Hertz T, Levy S, Ostrivsky D, Oppenheimer H, Zismanov S, Ku A, et al. Correlates of protection for booster doses of the BNT162b2 vaccine. MedRxiv 2022.07.16.22277626; doi: https://doi.org/10.1101/2022.07.16.22277626 DOI: https://doi.org/10.1038/s41467-023-39816-4
  81. Planas D, Staropoli I, Porot F, Guivel-Benhassine F, Handala L, Prot M, et al. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med (N Y). 2022 Dec;3(12):838–847.e3. 10.1016/j.medj.2022.09.010 DOI: https://doi.org/10.1016/j.medj.2022.09.010
  82. Waltz E. How nasal-spray vaccines could change the pandemic. Nature. 2022 Sep;609(7926):240–2. 10.1038/d41586-022-02824-3 DOI: https://doi.org/10.1038/d41586-022-02824-3
  83. Waltz E. China and India approve nasal COVID vaccines - are they a game changer? Nature. 2022 Sep;609(7927):450. 10.1038/d41586-022-02851-0 DOI: https://doi.org/10.1038/d41586-022-02851-0

Most read articles by the same author(s)